Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–
associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

Background Cabozantinib has shown clinical activity in combination with checkpoint
inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab …

379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the
STRIDE (Single T Regular Interval D) regimen, formerly T300+ D, showed encouraging …

Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV)
infection. The use of guideline-recommended nucleos (t) ide analogs with high barrier to …

Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and
platelet‐derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit …

Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory
disease. The appropriate treatment according to the Global Initiative for Chronic Obstructive …

Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in
combination with sorafenib in patients with RAS-mutated hepatocellular carcinoma (HCC) …

Hepatocellular carcinoma (HCC), the sixth most common cancer worldwide, has an
incidence rate equal to mortality. Over 80% of HCC cases occur within a high‐risk …

Background Hypertensive crisis is an urgent/emergency condition. Although obstructive
sleep apnea (OSA) in resistant hypertension has been thoroughly examined, information …

Background: The objectives of this phase II study were to determine the clinical activity of the
MET tyrosine kinase inhibitor capmatinib (INC280) in patients with MET-dysregulated …